Inhaled Therapies for Tuberculosis and Other Infectious Disease
Products, Technologies, and Procedures for Efficiently Treating Pulmonary Diseases
RTI is pleased to be a Gold Sponsor of the fourth international meeting on Inhaled Therapies for Tuberculosis and Other Infectious Disease. After previously convening in India, Japan, and Italy, this year's event comes to the Research Triangle in North Carolina.
The incidence of multiple and extensively drug-resistant tuberculosis and increase in resistant non-tuberculous mycobacterium, particularly M. abscessus, converge to present an urgent unmet medical need for which aerosol therapy may be valuable. In addition, infections associated with other diseases such as cystic fibrosis and chronic obstructive pulmonary disease may be effectively targeted with inhaled drugs.
This meeting brings together the community of biological and pharmaceutical scientists, engineers, and clinicians to consider progress in the field since the last convocation. Session topics include the following:
- Mycobacterial Landscape
- Host Response
- Inhaled Vaccine
- Formulations and Devices
- Inhaled Therapies
- Clinical Trials.
RTI’s Tony Hickey is on the organizing committee for this year's meeting on Inhaled Therapies for Tuberculosis and Other Infectious Disease and will serve as a session chairperson. Hickey is a Distinguished Fellow, Aerosol and Nanomaterials Engineering, with expertise in pulmonary biology, aerosol technology, powder dynamics, and pharmacokinetics and drug disposition.